Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by KalVista Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces $58 Million Registered Direct Offering
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
Tickers KALV
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.